Comparing the current results to its competitors, Arcus Biosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by -74.38 %, despite the revenue increase by the most of its competitors of 5.25 %, recorded in the same quarter.
October 29, 2025
In the fast-evolving landscape of biopharmaceutical innovation, Arcus Biosciences, Inc. (NYSE:RCUS) stands at the forefront, dedicated to shaping the future of cancer treatment with its advanced therapeutic strategies and promising clinical results. The company, which operates on a global scale, focuses on developing differentiated molecules and combination therapies targeting cancer, inflammatory, and autoimmune diseases. Arcus recently unveiled its financial results for the third quarter ended September 30, 2025, alongside an update on its robust pipeline of clinical-stage investigational molecules. A momentous announcement was also made regarding new employment inducement grants, reaffirming Arcus s commi...
February 18, 2025
Arcus Biosciences Fortifies Oncology Pipeline and Financial Position with Strategic Moves Arcus Biosciences, Inc. (NYSE:RCUS), a trailblazing entity in the sphere of clinical-stage global biopharmaceutical research, recently announced transformative advancements in its pursuit of novel cancer therapies. This Hayward, California-based company has signaled commendable progress by retaining full rights to casdatifan, a potentially best-in-class HIF-2a inhibitor, and successfully securing a $150 million common stock offering. These developments underscore Arcus Biosciences unwavering commitment to spearheading next-generation oncology treatments and bolstering its financial foundation.The expiration of Gilead s...
February 17, 2025
At the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Arcus Biosciences, Inc. (NYSE: RCUS) unveiled promising new data for its lead investigational drug, casdatifan, a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, indicating its potential as a best-in-class treatment option for patients with metastatic kidney cancer. The presentation was delivered by renowned researcher Dr. Toni K. Choueiri from the Dana-Farber Cancer Institute, who highlighted the significant implications of these findings.Casdatifan operates by selectively inhibiting the HIF-2α pathway, which plays a crucial role in tumor growth and survival in cancers, particularly in renal cell carcinoma....
October 9, 2024
Harnessing Innovation in Oncology: Arcus Biosciences Poised to Unveil Pioneering ARC-20 Study Data at the 2024 EORTC-NCI-AACR Symposium HAYWARD, Calif. A beacon of innovative cancer research, Arcus Biosciences, Inc. (NYSE: RCUS), is preparing to make significant waves at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Scheduled to be held from the 23rd to the 25th of October in Barcelona, Spain, this event will witness Arcus Biosciences presenting its first-ever clinical data from the ARC-20 study, among four accepted abstracts. As a clinical-stage global biopharmaceutical company, Arcus is steadfast in its quest to discover and develop pioneering and differentiated oncolo...
October 3, 2024
Arcus Biosciences, Inc. a clinical-stage biopharmaceutical company, is gaining traction in the cancer treatment landscape through strategic collaborations and innovative therapies. This article examines significant recent developments at Arcus, including partnerships with AstraZeneca and Taiho Pharmaceutical, as well as the completion of patient enrollment for a Phase 3 trial involving domvanalimab. These initiatives underscore the company s commitment to advancing differentiated cancer therapies and the potential implications for its market position and therapeutic portfolio. As the field of oncology continues to evolve, the development of combination therapies has emerged as a potent strategy to enhance t...
May 9, 2024
Arcus Biosciences Reports Strong Financial Results and Promising Pipeline Update for Q1 2024Hayward, Calif. - Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer patients, announced its financial results for the first quarter ended March 31, 2024. In addition to the impressive financial figures, Arcus Biosciences provided an exciting update on its clinical-stage investigational molecules targeting various pathways, including TIGIT, the adenosine axis, HIF-2a, AXL, and PD-1, across multiple common cancers.The quarterly financial results demonstrated significant growth and success for Arcus Biosciences. The company announced a...
December 4, 2023
Exelixis and Arcus Biosciences Collaborate in Groundbreaking Trial to Combat Advanced Renal Cell Carcinoma ALAMEDA, Calif. and HAYWARD, Calif. - Biopharmaceutical giants Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) have joined forces in an exciting clinical trial collaboration for STELLAR-009. This phase 1b/2 trial aims to evaluate the potential of zanzalintinib, Exelixis cutting-edge tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2, in patients battling advanced solid tumors, including clear cell renal cell carcinoma (ccRCC). Renal cell carcinoma, a type of kidney cancer, is notoriously difficult to treat in its advanced ...
Synlogic Inc's business model revolves around utilizing synthetic biology to develop innovative microbial engineering solutions. They focus on developing Synthetic Biotic medicines, which are living medicines designed to treat diseases by targeting specific metabolic or immuno-inflammatory pathways in the body.
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Sources:
Arcus Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Arcus Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
